COVID-19 and Rhino-orbital Mucormycosis

Mucormycosis Clinical Trial

Official title:

Clinical Profile and Outcome of Post Covid-19 Rhino-orbital Fungal Mucormycosis in Minia Governorate

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05212961
• Other study ID #: Ophthalmology
• Status: Completed
• Start date: December 28, 2021
• Est. completion date: September 28, 2023

Study information

• Verified date: October 2023
• Source: Minia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Detect the clinical presentation and outcome of post covid-19 fungal mucormycosis in patients referred to Minia university Hospital.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: September 28, 2023
• Est. primary completion date: June 28, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Patients who had positive PCR test for Covid-19.

2. Fungal rhino-orbital infection was confirmed.

Exclusion Criteria:

1. Suspected patient with COVID-19 not confirmed with PCR

2. Incomplete data

Related Conditions & MeSH terms

• Mucormycosis
• Zygomycosis

Locations

Country	Name	City	State
Egypt	Faculty of Medicine- Minia University	Minya

Sponsors (1)

Lead Sponsor	Collaborator
Minia University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Outcome of rhino-orbital mucormycosis in COVID-19 patients	Data of the patients who had post Covid-19 fungal mucormycosis in the last year will be revised to detect clinical presentation and final outcome	9 months